...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PLOS Neglected Tropical Diseases >Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
【24h】

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa

机译：伊维菌素，二乙基卡巴嗪和阿苯达唑（IDA）三联疗法在加速非洲消除淋巴丝虫病和盘尾丝虫病中的潜在价值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Global Program to Eliminate Lymphatic Filariasis (GPELF) has made significant progress in many countries. GPELF has delivered 5,600 million treatments to more than 763 million people living in 61 countries between the years 2000 and 2014, and it was estimated to have prevented 36 million clinical cases and saved 175 million disability adjusted life years (DALYs) [1]. Although elimination of LF is a major goal of the London Declaration on Neglected Tropical Diseases (NTDs), it is unlikely that LF will be eliminated by the target year of 2020 [2]. The key strategy of the elimination program comprises repeated annual rounds of mass drug administration (MDA) to populations at risk of acquiring the infection with diethylcarbamazine (DEC) plus albendazole outside of Africa and with ivermectin plus albendazole in Africa [3]. MDA reduces microfilariae (Mf) in human blood that are necessary for transmission by mosquito vectors, and one aim of the program is to interrupt transmission. Repeated rounds of MDA are required because current regimens fail to kill all adult worms and completely clear Mf following single-dose treatments. Successful programs have sustained annual MDA with high compliance for several years. Seventy-three countries were considered to be endemic for LF in 2015, and 55 of them still required MDA [4]. The GPELF has lagged in sub-Saharan Africa, where only 2 of 35 LF-endemic countries have stopped MDA and started post-MDA surveillance. Many countries in this region have either not started MDA or have less than 65% geographical coverage. Hence, a more effective treatment strategy could have a major impact on LF elimination in Africa.
机译：消除淋巴丝虫病全球方案（GPELF）在许多国家取得了重大进展。从2000年到2014年，GPELF已为61个国家/地区的7.63亿人提供了56亿种治疗方法，据估计已预防了3600万例临床病例，挽救了1.75亿例残疾调整生命年（DALYs）[1]。尽管消除LF是《关于被忽视的热带病的伦敦宣言》（NTDs）的主要目标，但在2020年的目标年之前消除LF是不太可能的[2]。消除计划的关键策略包括对非洲以外的有二乙基卡巴嗪（DEC）加阿苯达唑和非洲伊维菌素加阿苯达唑感染风险的人群进行每年一次的大规模药物管理（MDA）[3]。 MDA减少了人类血液中通过蚊媒传播所需的微丝aria（Mf），该程序的目的之一是中断传播。由于目前的治疗方案无法杀死所有成虫，并且在单剂量治疗后无法完全清除Mf，因此需要重复进行MDA。成功的计划已连续数年保持了年度MDA的高度合规性。 2015年，有73个国家被认为是LF的地方病，其中55个国家仍需要MDA [4]。 GPELF在撒哈拉以南非洲落后，在35个LF流行国家中，只有2个停止了MDA并开始了MDA后的监测。该地区的许多国家尚未启动MDA或地理覆盖率不到65％。因此，更有效的治疗策略可能会对非洲消除LF产生重大影响。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号